Stem Cell Therapeutics (SSS)

[janetcanada]

Stem Cell Therapeutics Corp. Announces Dr. Alan Moore's Presentation at the BioFinance 2010 Meeting April 6-8, 2010, Toronto, Canada

CALGARY, ALBERTA, Apr 06, 2010 (MARKETWIRE via COMTEX News Network) --
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT") today announced that Dr. Alan Moore, President CEO of SCT, will be presenting on behalf of SCT at the BioFinance 2010 meeting which is being held in Toronto, Canada, April 6-8, 2010.

Dr. Alan Moore will be speaking at 9:30 a.m., on April 7th, 2010, in the Simcoe Room of the Toronto Marriott Eaton Centre. Dr. Moore's presentation will discuss the progress that SCT has made in 2009 and the future direction that company will pursue in 2010 with its product line.

Dr. Alan Moore, President and CEO of SCT, commented as follows:

"We are excited to have this opportunity to communicate with the BioFinance community on our Company's achievements and the future potential of SCT as we continue our product development.

Our outlook for this year includes:

- Completion of Phase IIb stroke trial patient analysis and announcement of top-line results;- The opportunity to build on our strengths with the initiation of additional clinical programs in Traumatic Brain Injury and Multiple Sclerosis."
About the BioFinance 2010 meeting (http://www.biofinance.ca/): BioFinance 2010 is the leading investor conference in Canada for the life sciences industry. This three-day event brings together key industry players interested in investment opportunities and issues affecting companies in the life sciences sector. Presenting companies will span a range of industries including: biologics, medical devices, drug delivery, vaccines, diagnostics, bio-energy, green technologies, bio materials, industrial biotech, and research services.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available. Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.